We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Original Contribution |  FREE
Samer S. Najjar, MD; Sunil V. Rao, MD; Chiara Melloni, MD, MHS; et al.
JAMA. 2011;305(18):1863-1872. doi:10.1001/jama.2011.592.
Includes: Supplemental Content

Editorial | 
Deepak L. Bhatt, MD, MPH
JAMA. 2011;305(18):1908-1909. doi:10.1001/jama.2011.600.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal
From The JAMA Network
JAMA Internal Medicine
Original Investigation  | 
Nononcologic Use of Human Recombinant Erythropoietin Therapy in Hospitalized Patients
Michael A. Fischer, MD, MS; Charles A. Morris, MD, MPH; Wolfgang C. Winkelmayer, MD, ScD; et al.
JAMA Internal Medicine
Editor's Correspondence  | 
Erythropoietin Resistance During Androgen Deficiency—Reply
Jerry L. Spivak, MD
JAMA Internal Medicine
Review Article  | 
Epoetin Alfa:  Clinical Evolution of a Pleiotropic Cytokine
David H. Henry, MD; Peter Bowers, MD; Michael T. Romano, PhD; et al.
JAMA Pediatrics
Article  | 
Comparison of 2 Iron Doses in Infants Receiving Recombinant Human Erythropoietin Therapy
Shahid Nazir, MD; Ricardo L. Peverini, MD; Douglas D. Deming, MD; et al.